Dr. Pravin Jadhav is Senior Director of Applied Innovation within Otsuka Pharmaceutical Development and Commercialization (OPDC). He leads a multi-disciplinary team of data, information and knowledge experts to create science-driven, technology-enabled solutions of clinical and economic utility. The team is focused on clinical trial transformation and new business model by leveraging digital technology to bring therapeutic solutions for customers.
Before joining Otsuka, Dr. Jadhav was Director of Modeling and Simulation at Merck for 4 years. He was a leader of scientific network on Predicting Competitive Advantage for all therapeutic areas. The group was charged with providing quantitative input for go/no-go decisions and key study design elements of head-to-head studies as well as quantitative assessment of competitive advantage for the key assets. He was also therapeutic area lead for immunology to plan and execute advanced research for high quality and cost effective drug development programs from discovery through commercialization.
Before joining Merck, he was Team Leader and Expert Regulatory Scientist in the Division of Pharmacometrics of the Office of Clinical Pharmacology (OCP) at the US food and Drug Administration (FDA). He has worked on more than 100 New Drug Applications and 150 Investigational New Drug applications covering aspects of exposure–response to aid in important regulatory decisions. He covered various therapeutic areas such as anti-viral, anti-infective, transplant, reproductive and urology, cardiovascular and renal, dermatology, and medical counter measures (MCM) products in 9 years at FDA. Pravin represented OCP as an internal expert on clinical pharmacology issues in pediatric drug development advising all the Office of New Drugs (OND) divisions as an appointed member of the Pediatric Review Committee (PeRC), a committee mandated by the congress. He has more than 150 publications in peer reviewed journals and presentations at international conferences. He has received several awards and honors at the FDA, including outstanding service award in 2008 and special citation for innovative analysis on telaprevir and boceprevir new drug applications in 2011.
Pravin received his BPharm and MPharm from India, PhD in Pharmaceutical Sciences from the Medical College of Virginia Commonwealth University (VCU) and MPH from Johns Hopkins University, Bloomberg School of Public Health. He has an adjunct faculty appointment in the College of Pharmacy at University of Florida and member of the Graduate Advisory Board of VCU School of Pharmacy.